# Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures

> **NCT00655551** · PHASE3 · COMPLETED · sponsor: **UCB BIOSCIENCES, Inc.** · enrollment: 100 (actual)

## Conditions studied

- Partial Epilepsies
- Partial Onset Seizures

## Interventions

- **DRUG:** lacosamide
- **DRUG:** lacosamide
- **DRUG:** lacosamide

## Key facts

- **NCT ID:** NCT00655551
- **Lead sponsor:** UCB BIOSCIENCES, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2018-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00655551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00655551, "Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00655551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*